Oximes (i.e., C=n-o-) Patents (Class 514/640)
  • Patent number: 11026427
    Abstract: Compounds of the Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 8, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Thomas James Hoffman, Daniel Stierli, Martin Pouliot
  • Patent number: 10544092
    Abstract: Disclosed is a malononitrile oxime ether compound having a novel structure as shown in the general formula I. Respective substituents in the general formula I as defined in the specification. The compound of the general formula I exhibits an excellent microbicidal activity, and can effectively prevent and treat plant diseases caused by bacteria and fungi. Also provided is a use of the compound of the general formula I as a microbicide in the agricultural and other fields.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 28, 2020
    Assignee: SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD.
    Inventors: Xueming Cheng, Lixin Zhang, Liang Chen, Qin Sun, Junli Liu, Zhinian Li, Jie Zhao, Jingbo Xu, Hongfei Wu
  • Patent number: 9227937
    Abstract: Phenoxyalkyl pyridinium oxime compounds for use in treating organophosphate poisoning.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: January 5, 2016
    Assignee: Mississippi State University
    Inventors: Janice E. Chambers, Howard W. Chambers, Edward C. Meek
  • Patent number: 9045393
    Abstract: The invention relates to compounds of formula (I): where X+Y=keto, or X=OH and Y=H, or X+Y=oxime or methyloxime, B=OH and C+D=H, or C+D=C1-C4 linear or branched alkyl, or C=H and D=C1-C4 linear or branched alkyl, or B+C=keto and D=methyl, hydroxyl, or methylamino, or B and C=H and D=methylamino, or B+C=oxime and D=methyl and R=C1-C10 linear or branched alkyl, the salts, esters, or salts of esters thereof as medicament, in particular as neuroprotectors, novel compounds of formula (I) and pharmaceutical compositions.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 2, 2015
    Assignee: TROPHOS
    Inventors: Thierry Bordet, Cyrille Drouot
  • Publication number: 20150133495
    Abstract: Disclosed herein is a compound of Formula I or a pharmaceutically acceptable salt thereof, in which A, G, R1 and R2 are as defined herein. The compounds and pharmaceutical compositions of the compounds are suitable for the treatment of HCV infection in mammals and are also useful to modulate or inhibit NS3/4 dimerization.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventor: Daniel Lamarre
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150056269
    Abstract: The present invention relates to a novel galenic form of cholesterol derivative. More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.
    Type: Application
    Filed: August 22, 2012
    Publication date: February 26, 2015
    Applicant: TROPHOS
    Inventors: Corinne Chaimbault, Magali Michaud, Patrick Berna, Sophie Schaller, Firas Bassissi, Simon Eastman
  • Patent number: 8956604
    Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 17, 2015
    Assignee: The University of Kansas
    Inventors: Cory Berkland, Joshua Sestak
  • Publication number: 20150025086
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Publication number: 20150025110
    Abstract: This invention relates to novel 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Henrietta Dehmlow, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Hans Richter
  • Publication number: 20150010469
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Applicants: British Columbia Cancer Agency Branch, University of British Columbia
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar
  • Patent number: 8912214
    Abstract: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: December 16, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Yves Pommier, Robert H. Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson
  • Patent number: 8877784
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • Publication number: 20140303255
    Abstract: Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the formula I: wherein R, R1, R2, R3, R4, R5 and R6 are as defined herein.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 9, 2014
    Inventors: Mrunalini S. Dhamdhere, George D. Green, Shao-Ching Hung, Raymond J. Swedo
  • Patent number: 8846719
    Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 30, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
  • Publication number: 20140288184
    Abstract: The present invention provides a glyoxime derivative displaying excellent pesticidal effect or a salt thereof and a pesticide containing the same as an active ingredient. This pesticide is characterized by containing as an active ingredient, a glyoxime derivative expressed by the general formula [I] (in which X represents a cyano group or a carbamoyl group, R1 represents a C1˜C8 alkyl group, a C3˜C6 cycloalkyl C1˜C6 alkyl group, etc, and IV represents a hydrogen atom, a C1˜C8 alkyl group, a C3˜C6 cycloalkyl C1˜C6 alkyl group, etc.) or an agriculturally acceptable salt thereof.
    Type: Application
    Filed: November 19, 2012
    Publication date: September 25, 2014
    Applicants: IHARA CHEMICAL INDUSTRY CO., LTD., KUMIAI CHEMICAL INDUSTRY CO., LTD.
    Inventors: Shunichirou Fukumoto, Daisuke Shikama, Toshihiro Nagata, Katsuya Kato, Kei Kawamoto, Masaaki Komatsu, Takeshi Matsuda, Seisuke Ito
  • Patent number: 8841300
    Abstract: A new treatment methodology and pharmacological composition for the treatment and remission of Parkinson's Disease and other neurological diseases are provided. The medication and treatment are based on the use of a combination of a phosphodiesterase inhibitor medication, commonly used to treat male erectile dysfunction, and a high-dose of serotonergic synaptic reuptake inhibitor medication, commonly used to treat depression, anxiety disorders, obsessive compulsive disorder and various panic phobias. The treatment regime is based upon the discovery that the primary cause of PD and various other related neurological conditions is dysfunction in the serotonergic pathways involving the brainstem, nucleus of Raphe, and various projecting serotonergic fibers.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: September 23, 2014
    Inventor: Jerry M. Held
  • Publication number: 20140275166
    Abstract: Spin-traps and spin labels and their reduction products are claimed for the treatment of peri- and post-menopausal syndrome.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 18, 2014
    Inventor: Peter Herbert Proctor
  • Publication number: 20140275198
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.
    Type: Application
    Filed: February 11, 2014
    Publication date: September 18, 2014
    Applicant: Korea Basic Science Institute
    Inventors: Gun-Hwa Kim, Soohyun Kim, Jong-Soon Choi, Seung II Kim, Edmond Changkyun Park
  • Publication number: 20140235604
    Abstract: A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 21, 2014
    Inventors: Krzysztof Palczewski, Akiko Maeda, Marcin Golczak
  • Publication number: 20140221473
    Abstract: Embodiments of the present disclosure provide compositions including ketamine analogues, salts, and disalts, pharmaceutical compositions including ketamine analogues, salts, or disalts, methods of treatment of a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Application
    Filed: June 29, 2012
    Publication date: August 7, 2014
    Inventors: Jahanshah Amin, Kirpal S. Bisht, Meghanath Gali
  • Publication number: 20140213589
    Abstract: The invention relates to hydroxyphenyl derivatives of formula (I); and uses thereof as anti-bacterial and/or anti-parasitic agents.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: FAB PHARMA S.A.S.
    Inventors: Alexis DENIS, Vincent Gerusz, Yannick Bonvin
  • Publication number: 20140200234
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 17, 2014
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Rheal A. TOWNER, Robert A. FLOYD
  • Patent number: 8772345
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 8, 2014
    Assignee: Southwest Research Institute
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Publication number: 20140187580
    Abstract: Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the treatment of rectal hemorrhoids and rectal fissures.
    Type: Application
    Filed: February 4, 2014
    Publication date: July 3, 2014
    Inventor: Peter H. Proctor
  • Patent number: 8759350
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Grant
    Filed: December 25, 2003
    Date of Patent: June 24, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Patent number: 8758788
    Abstract: Active compound mixtures comprising ipconazole and at least one further fungicidally active compound are highly suitable for protecting industrial materials against colonization and destruction by microorganisms.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: June 24, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Rainer Bruns, Martin Kugler, Thomas Jaetsch
  • Publication number: 20140135393
    Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.
    Type: Application
    Filed: April 11, 2012
    Publication date: May 15, 2014
    Applicant: Council of Scientific & Industrial Research
    Inventors: Santu Bandyopadhyay, Balaram Ghosh, Parasuraman Jaisankar, Bikas Chandra Pal, Siddhartha Roy, Balaram Ghosh, Parasuraman Jaisankar, Bikas Pal, Nahid Ali, Siddhartha Roy, Bholanath Paul, Arjun Ram, Siddhartha Roy, Bholanath Paul, Arjun Ram, Ulaganathan Mabalirajan, Nahid Ali, Arun Bandopadhyay, Aditya Konar, Jayashree Bagchi Chakraborty, Indrani Chowdhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, Anirban Manna, Roma Sinha, Prayot Bhattacharya, Jayaraman Vinayagam, Deba Prasad Jana, Sushovan Chowdhury
  • Patent number: 8722669
    Abstract: A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: May 13, 2014
    Assignee: Case Western Reserve University
    Inventors: Krzysztof Palczewski, Akiko Maeda, Marcin Golczak
  • Patent number: 8633249
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: January 21, 2014
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Rheal A. Towner, Robert A. Floyd
  • Publication number: 20130281538
    Abstract: The present invention is directed to a formulation and associated method for neutralizing one or more toxic chemical and/or materials including toxic industrial chemicals and toxic industrial materials, such as irritants, heavy metals, radioactive metals, acids and acid irritants, pesticides, and various agricultural chemicals, (collectively referred to as toxic chemical, materials, or simply toxins) as well as decontaminating surfaces that have come into contact with these agents. As a result, the formulation of the present invention can be used for neutralizing a broad spectrum of toxic chemicals and materials. In one embodiment, the active ingredient comprises 2, 3, butanedione monoxime (also known as diacetyl monoxime (DAM)), and alkali salts thereof such as potassium 2,3-butanedione monoxime (KBDO). The formulation also typically includes a carrier in which the active ingredient is dispersed.
    Type: Application
    Filed: June 18, 2013
    Publication date: October 24, 2013
    Inventors: Timothy G. Henry, Barbara B. Price
  • Publication number: 20130267604
    Abstract: Provided are protected antimicrobial compounds which are useful for controlling microorganisms in aqueous or water-containing systems, such as oil or gas field fluids, at elevated temperature. The antimicrobial compounds are of the formula I: wherein R3 and R4 are as defined herein.
    Type: Application
    Filed: November 29, 2011
    Publication date: October 10, 2013
    Applicants: DOW GLOBAL TECHNOLOGIES LLC, ANGUS CHEMICAL COMPANY
    Inventors: Charles E. Coburn, Michael V. Enzien, Heather R. Mcginley, David W. Moore
  • Patent number: 8536157
    Abstract: The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: September 17, 2013
    Assignee: The University of Melbourne
    Inventors: Alastair Stewart, Martin Banwell, Brenda Leung, Anu Augustine, Jacki Kitching, Thomasz Bilski
  • Patent number: 8536120
    Abstract: The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: September 17, 2013
    Assignee: The Administrators of The Tulane Educational Fund
    Inventors: Cyril Y. Bowers, Gloria S. Tannenbaum, David H. Coy, Simon J. Hocart
  • Publication number: 20130217674
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Application
    Filed: August 22, 2011
    Publication date: August 22, 2013
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Publication number: 20130217673
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of mixed monoamine reuptake inhibitor locally at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least thirty days. In some embodiments, the relief can be for at least at least fifty days, at least one hundred days, at least one hundred and twenty days, at least one hundred and thirty, at least one hundred fifty days or at least one hundred and eighty days.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 22, 2013
    Applicant: Warsaw Orthopedic, Inc
    Inventor: Jared T. Wilsey
  • Patent number: 8492441
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: July 23, 2013
    Assignee: Novartis AG
    Inventor: Eric Legangneux
  • Patent number: 8475850
    Abstract: Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: July 2, 2013
    Assignee: Metaproteomics, LLC
    Inventors: Matthew L. Tripp, Veera Konda, Amy J. Hall, Anu Desai, Jeffrey S. Bland
  • Publication number: 20130144103
    Abstract: The present invention is directed to a formulation and associated method for neutralizing one or more toxic chemical and/or materials including toxic industrial chemicals and toxic industrial materials, such as irritants, heavy metals, radioactive metals, acids and acid irritants, pesticides, and various agricultural chemicals, (collectively referred to as toxic chemical, materials, or simply toxins) as well as decontaminating surfaces that have come into contact with these agents. As a result, the formulation of the present invention can be used for neutralizing a broad spectrum of toxic chemicals and materials. In one embodiment, the active ingredient comprises 2, 3, butanedione monoxime (also known as diacetyl monoxime (DAM)), and alkali salts thereof such as potassium 2,3-butanedione monoxime (KBDO). The formulation also typically includes a carrier in which the active ingredient is dispersed.
    Type: Application
    Filed: October 28, 2011
    Publication date: June 6, 2013
    Applicant: E-Z-EM, INC.
    Inventors: Timothy G. Henry, Barbara B. Price
  • Patent number: 8440671
    Abstract: The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiestersa-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: May 14, 2013
    Assignee: Vivus, Inc.
    Inventor: Jerry M. Held
  • Publication number: 20130109718
    Abstract: This invention relates to novel 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.
    Type: Application
    Filed: October 24, 2012
    Publication date: May 2, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Patent number: 8420595
    Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds from the family of antioxidant compounds including, but not limited to, N-acetylcysteine (NAC), Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine and carbamathione. The compositions of the current invention may be delivered by injections or orally.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 16, 2013
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Richard Dana Kopke, Robert A. Floyd
  • Publication number: 20130065850
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 14, 2013
    Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
  • Patent number: 8338488
    Abstract: The invention relates to the use of at least one oxime derivative of 3,5-seco-4-norcholestane as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: December 25, 2012
    Assignee: Trophos
    Inventors: Rebecca Pruss, Cyrille Drouot
  • Publication number: 20120316136
    Abstract: The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 13, 2012
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima KHAIRATKAR-JOSHI, Abhay KULKARNI, Indranil MUKHOPADHYAY, Vidya Ganapati KATTIGE, Vikram Mansingh BHOSALE, Dinesh Pradeep WALE, Abraham THOMAS, Sukeerthi KUMAR, Sachin Sundarlal CHAUDHARI
  • Patent number: 8318780
    Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: November 27, 2012
    Assignee: Intermune, Inc.
    Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
  • Publication number: 20120295895
    Abstract: A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 22, 2012
    Inventors: Krzysztof Palczewski, Akiko Maeda, Marcin Golczak
  • Publication number: 20120295886
    Abstract: The present disclosure provides compounds having affinity for the M2 proton channel, useful for the treatment of viral infections such as influenza, which are of the Formula (I): wherein R1, R2, and Y are as defined herein. Methods of preparing the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds in the treatment of viral infections such as influenza are also provided.
    Type: Application
    Filed: May 18, 2012
    Publication date: November 22, 2012
    Applicant: INFLUMEDIX, INC.
    Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
  • Patent number: 8293708
    Abstract: Pharmaceutical compositions comprising pegylated growth hormone at pH 7 or below are provided.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: October 23, 2012
    Assignee: Novo Nordisk Health Care A/G
    Inventor: Mats Reslow
  • Publication number: 20120245129
    Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression.
    Type: Application
    Filed: December 5, 2011
    Publication date: September 27, 2012
    Inventors: Yves-Alain Barde, Graeme Bilbe, Ruben Deogracias, Rainer R. Kuhn, Tomoya Matsumoto, Anis Khusro Mir, Anna Svenja Schubart